DE60110914D1 - Verbindungen und ihre verwendung als hemmer des glycintransports - Google Patents

Verbindungen und ihre verwendung als hemmer des glycintransports

Info

Publication number
DE60110914D1
DE60110914D1 DE60110914T DE60110914T DE60110914D1 DE 60110914 D1 DE60110914 D1 DE 60110914D1 DE 60110914 T DE60110914 T DE 60110914T DE 60110914 T DE60110914 T DE 60110914T DE 60110914 D1 DE60110914 D1 DE 60110914D1
Authority
DE
Germany
Prior art keywords
glycin
inhibitors
transport
compounds
glycin transport
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60110914T
Other languages
English (en)
Other versions
DE60110914T2 (de
Inventor
Knud Moltzen
Paul Smith
Christian Krog-Jensen
Peter Bogeso
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Application granted granted Critical
Publication of DE60110914D1 publication Critical patent/DE60110914D1/de
Publication of DE60110914T2 publication Critical patent/DE60110914T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/14—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of carbon skeletons containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/72—Benzo[c]thiophenes; Hydrogenated benzo[c]thiophenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
DE60110914T 2000-07-21 2001-07-19 Verbindungen und ihre verwendung als hemmer des glycintransports Expired - Fee Related DE60110914T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200001124 2000-07-21
DK200001124 2000-07-21
PCT/DK2001/000510 WO2002008216A1 (en) 2000-07-21 2001-07-19 Novel compounds and their use as glycine transport inhibitors

Publications (2)

Publication Number Publication Date
DE60110914D1 true DE60110914D1 (de) 2005-06-23
DE60110914T2 DE60110914T2 (de) 2005-10-27

Family

ID=8159626

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60110914T Expired - Fee Related DE60110914T2 (de) 2000-07-21 2001-07-19 Verbindungen und ihre verwendung als hemmer des glycintransports

Country Status (28)

Country Link
US (1) US6921774B2 (de)
EP (1) EP1301502B1 (de)
JP (1) JP2004504393A (de)
KR (1) KR20030015889A (de)
CN (1) CN100509791C (de)
AR (1) AR032358A1 (de)
AT (1) ATE295844T1 (de)
AU (2) AU2001281740B2 (de)
BG (1) BG107530A (de)
BR (1) BR0113011A (de)
CA (1) CA2416447A1 (de)
CZ (1) CZ2003396A3 (de)
DE (1) DE60110914T2 (de)
EA (1) EA005621B1 (de)
ES (1) ES2238466T3 (de)
HR (1) HRP20030053A2 (de)
HU (1) HUP0302778A3 (de)
IL (2) IL153988A0 (de)
IS (1) IS6693A (de)
MX (1) MXPA03000642A (de)
NO (1) NO20030243L (de)
NZ (1) NZ523720A (de)
PL (1) PL364439A1 (de)
PT (1) PT1301502E (de)
SK (1) SK2022003A3 (de)
UA (1) UA75081C2 (de)
WO (1) WO2002008216A1 (de)
ZA (1) ZA200300514B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006524642A (ja) * 2003-04-30 2006-11-02 ハー・ルンドベック・アクチエゼルスカベット 芳香族オキシフェニルおよび芳香族スルファニルフェニル誘導体
US20060223857A1 (en) * 2003-08-21 2006-10-05 Michael Didriksen Combination of a serotonin reuptake inhibitor and a glycine transporter type 1 inhibitor for the treatment of depression
US7163954B2 (en) * 2003-09-25 2007-01-16 Wyeth Substituted naphthyl benzothiophene acids
JP2007528879A (ja) * 2004-03-12 2007-10-18 ハー・ルンドベック・アクチエゼルスカベット フェニルインダン誘導体
WO2005100301A1 (en) * 2004-03-31 2005-10-27 Eli Lilly And Company 2-aryloxyethyl glycine derivatives and their use as glycine transport inhibitors
WO2006000222A2 (en) * 2004-06-24 2006-01-05 H. Lundbeck A/S The combination of an antipsychotic and a glycine transporter type i inhibitor for the treatment of schizophrenia
EP2042480B1 (de) 2006-07-18 2013-05-01 Astellas Pharma Inc. Aminoindanderivate oder salze davon
KR101097533B1 (ko) * 2006-08-30 2011-12-22 에프. 호프만-라 로슈 아게 Ｇｌｙｔ-1 억제제
US20100083581A1 (en) * 2007-06-18 2010-04-08 Mattice Douglas A Environmental brush seal
ES2615884T3 (es) 2009-01-20 2017-06-08 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Ácido sórbico y benzoico y sus derivados que aumentan la actividad de un neurofármaco
EP2380595A1 (de) 2010-04-19 2011-10-26 Nlife Therapeutics S.L. Zusammensetzungen und Verfahren zur selektiven Abgabe von Oligonukleotidmolekülen an spezifische Neuronentypen
US9700563B2 (en) * 2012-09-06 2017-07-11 MediSynergies, LLC Kappa opioid receptor compounds

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1166711A (en) * 1966-03-28 1969-10-08 Kefalas As Process for the Preparation of Phenyl-Indane and -Tetralin Derivatives
US3549656A (en) 1967-12-28 1970-12-22 Kefalas As Antidepressant 1 - aminoalkyl - thiophthalanes and acid addition salts thereof
GB1526331A (en) * 1976-01-14 1978-09-27 Kefalas As Phthalanes
US5225323A (en) 1988-11-21 1993-07-06 Baylor College Of Medicine Human high-affinity neurotransmitter uptake system
WO1993010228A1 (en) 1991-11-12 1993-05-27 Synaptic Pharmaceutical Corporation Dna encoding a glycine transporter and uses thereof
US5824486A (en) 1996-05-31 1998-10-20 Allelix Neuroscience Inc. Glycine transporter-transfected cells and uses thereof
US6008015A (en) 1997-04-11 1999-12-28 Allelix Neuroscience Inc. Glycine transporter
AR021509A1 (es) * 1998-12-08 2002-07-24 Lundbeck & Co As H Derivados de benzofurano, su preparacion y uso
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
US6566550B2 (en) * 2001-06-21 2003-05-20 Pfizer Inc Substituted aromatic ethers as inhibitors of glycine transport

Also Published As

Publication number Publication date
EP1301502B1 (de) 2005-05-18
NO20030243L (no) 2003-03-06
DE60110914T2 (de) 2005-10-27
CZ2003396A3 (cs) 2003-05-14
AU2001281740B2 (en) 2006-02-16
EA005621B1 (ru) 2005-04-28
IL153988A0 (en) 2003-07-31
IS6693A (is) 2003-01-20
EP1301502A1 (de) 2003-04-16
PT1301502E (pt) 2005-09-30
ZA200300514B (en) 2004-08-20
NO20030243D0 (no) 2003-01-17
ES2238466T3 (es) 2005-09-01
JP2004504393A (ja) 2004-02-12
NZ523720A (en) 2004-07-30
HUP0302778A3 (en) 2005-02-28
ATE295844T1 (de) 2005-06-15
AU8174001A (en) 2002-02-05
US20030181445A1 (en) 2003-09-25
UA75081C2 (en) 2006-03-15
MXPA03000642A (es) 2003-06-06
HUP0302778A2 (hu) 2003-12-29
BG107530A (bg) 2003-09-30
HRP20030053A2 (en) 2005-02-28
US6921774B2 (en) 2005-07-26
EA200300180A1 (ru) 2003-06-26
CA2416447A1 (en) 2002-01-31
KR20030015889A (ko) 2003-02-25
IL153988A (en) 2006-10-05
PL364439A1 (en) 2004-12-13
BR0113011A (pt) 2003-07-01
AR032358A1 (es) 2003-11-05
CN100509791C (zh) 2009-07-08
WO2002008216A1 (en) 2002-01-31
CN1662519A (zh) 2005-08-31
SK2022003A3 (en) 2003-06-03

Similar Documents

Publication Publication Date Title
ATE244235T1 (de) Heterocyclische verbindungen als reversible inhibitoren von cysteinproteasen
DE60221233D1 (de) Neue spirotricyclische derivate und deren verwendung als phosphodiesterase-7-inhibitoren
ATE544750T1 (de) Lactamhaltige verbindungen und ihre derivate als faktor-xa-hemmer
DE60222006D1 (de) Heterozyklische verbindungen und ihre verwendungen
DE60232328D1 (de) Substituierte naphthylindolderivate und ihre verwendung als plasminogen aktivator inhibitor (pai-1) inhibitoren
DE60208661D1 (de) Diaminothiazole und ihre verwendung als cyclinabhängige kinase inhibitoren
ATE359276T1 (de) Aryloxyphenyl und arylsulfanylphenylderivate
DE60030574D1 (de) Fünfgliedrige derivate von heterozyklen und ihre verwendung als monoaminoxidase-inhibitoren
DE60221875D1 (de) 4-(6-gliedriger)-heteroaryl-acyl-pyrrolidin derivate als hcv-inhibitoren
DE60308387D1 (de) Pyrazolenthaltende zusammensetzungen und ihre verwendung als gsk-3 inhibitoren
ATE270278T1 (de) Phthalazinone pde iii/iv hemmer
DE60042501D1 (de) Piperazine Verbindungen als Tachykinin-Hemmer
DE69905582D1 (de) Heterocyclische verbindungen als rotamase-enzymen inhibitoren
ATE323081T1 (de) N-formylhydroxylamin verbindungen als inhibitoren von pdf
DE60113283D1 (de) Thiadiazole und oxadiazole sowie ihre verwendung als phosphodiesterase-7 inhibitoren
ATE329906T1 (de) Substituierte 2-anilino-benzimidazole und ihre verwendung als nhe-inhibitoren
DE60219068D1 (de) Substituierte 2-amino-zykloalkankarboxamide und ihre verwendung als zysteinprotease-inhibitoren
DE60110914D1 (de) Verbindungen und ihre verwendung als hemmer des glycintransports
DE60136178D1 (de) Verwendung von ketonen als vorstufen von aktiven verbindungen
DE50313157D1 (de) Phenylaminopyrimidine und ihre verwendung als rho-kinase inhibitoren
ATE245653T1 (de) Imidazolverbindungen als phosphodiesterase vii- hemmer
ATE287403T1 (de) 6-phenylbenzonaphthyidine
DE60036558D1 (de) Phthalazinon-derivate als pde 4 hemmer
DE60003045D1 (de) Heterozyclische verbindungen als angiogenese inhibitoren
DE60113689D1 (de) 2-aminothiazolinderivate und ihre verwendung als no-synthase inhibitoren

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee